Cagrilintide 5mg

Base Peptides are intended for licensed medical professionals and experienced researchers. Reconstitution required. Dosing and use instructions are not provided.

$118.00

Sale Sold out

Shipping calculated at checkout.

Quantity Single Vials Package of 5

Quantity

Cagrilintide — Long-Acting Amylin Analogue (DACRA: Amylin/Calcitonin Receptor Agonist)

Cagrilintide is a synthetic, long-acting analogue of the naturally-occurring hormone Amylin, engineered to **activate both amylin and calcitonin-family receptors** and deliver sustained effects on appetite regulation, gastric emptying, and metabolic signalling. [oai_citation:0‡Peptides.org](https://www.peptides.org/cagrilintide-a-comprehensive-peptide-overview/?utm_source=chatgpt.com)

Identifiers

CAS: 1415456-99-3 [oai_citation:1‡NovoPro Labs](https://www.novoprolabs.com/p/cagrilintide-319572.html?utm_source=chatgpt.com)
Development Codes / Synonyms: AM833, NNC0174-0833 [oai_citation:2‡Peptides.org](https://www.peptides.org/cagrilintide-a-comprehensive-peptide-overview/?utm_source=chatgpt.com)
MW (approx): ~4,409 Da [oai_citation:3‡NovoPro Labs](https://www.novoprolabs.com/p/cagrilintide-319572.html?utm_source=chatgpt.com)
Mechanism Class: Dual Amylin/Calcitonin Receptor Agonist (DACRA) [oai_citation:4‡Peptides.org](https://www.peptides.org/cagrilintide-a-comprehensive-peptide-overview/?utm_source=chatgpt.com)

How It Works (Plain English)

Amylin is a hormone secreted alongside insulin that helps the brain sense fullness, slows stomach emptying, and blunts post-meal glucose spikes. [oai_citation:5‡Synapse](https://synapse.patsnap.com/article/what-is-cagrilintide-used-for?utm_source=chatgpt.com)
Cagrilintide mimics amylin but is **modified** to last much longer and resist breakdown; it also engages calcitonin-family receptors to broaden its signalling profile. [oai_citation:6‡Creative Peptides](https://www.creative-peptides.com/resources/what-is-cagrilintide-peptide.html?utm_source=chatgpt.com)
By acting on these receptors, it supports **reduced appetite**, **delayed gastric emptying**, and improved metabolic responses — making it valuable in obesity and type 2 diabetes research. [oai_citation:7‡PubMed](https://pubmed.ncbi.nlm.nih.gov/36883831/?utm_source=chatgpt.com)

Why Researchers Use It

To study next-generation metabolic peptides beyond GLP-1 alone — exploring how appetite, satiety, and energy-balance pathways can be modulated via amylin signalling. [oai_citation:8‡American Chemical Society Publications](https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00565?utm_source=chatgpt.com)
To model **body-weight reduction**, **fat-mass change**, and metabolic health in obesity and diabetic animal or human models. [oai_citation:9‡PubMed](https://pubmed.ncbi.nlm.nih.gov/34798060/?utm_source=chatgpt.com)
To examine combination therapies (e.g., with GLP-1 agonists) for synergistic effects on weight and glycemic control. [oai_citation:10‡The New England Journal of Medicine](https://www.nejm.org/doi/full/10.1056/NEJMoa2502081?utm_source=chatgpt.com)

Key Studies — What Was Tested, What Changed, Why It Matters

Once-weekly dose finding in overweight/obesity (Phase 2)

What was tested: In a multicentre, randomised, double-blind, placebo-controlled dose-finding trial (weekly cagrilintide vs placebo) in people with overweight or obesity. [oai_citation:11‡PubMed](https://pubmed.ncbi.nlm.nih.gov/34798060/?utm_source=chatgpt.com)
What changed: Significant reductions in body weight — with tolerable safety profiles (gastrointestinal side-effects were the most frequent). [oai_citation:12‡PubMed](https://pubmed.ncbi.nlm.nih.gov/34798060/?utm_source=chatgpt.com)
Why it matters: Demonstrates that amylin-receptor targeting peptides can produce meaningful weight loss, supporting further research in metabolic disease. [oai_citation:13‡PubMed](https://pubmed.ncbi.nlm.nih.gov/36883831/?utm_source=chatgpt.com)

Cagrilintide + GLP-1 (Semaglutide) in Obesity + T2D (Phase 3a)

What was tested: Adults with overweight/obesity and type 2 diabetes assigned to once-weekly cagrilintide + Semaglutide 2.4 mg or placebo for 68 weeks. [oai_citation:14‡PubMed](https://pubmed.ncbi.nlm.nih.gov/40544432/?utm_source=chatgpt.com)
What changed: Mean weight change ~-13.7 % in the combination group vs -3.4 % in placebo during the study period. [oai_citation:15‡PubMed](https://pubmed.ncbi.nlm.nih.gov/40544432/?utm_source=chatgpt.com)
Why it matters: Highlights that combining amylin-pathway peptides with GLP-1 may enhance weight & metabolic outcomes — central to research strategies. [oai_citation:16‡Pharmacy Times](https://www.pharmacytimes.com/view/co-formulation-of-semaglutide-and-cagrilintide-shows-promise-against-diabetes-and-obesity?utm_source=chatgpt.com)

Potential Research Applications

Obesity & Weight-Management Models

Animal or human models of diet-induced obesity, body-composition tracking (fat vs lean change).
Appetite/feeding behaviour, satiety readouts, gastric-emptying studies.

Type 2 Diabetes & Metabolic Syndrome

Glucose tolerance tests, HbA1c reduction, insulin-secretion/insulin-sensitivity assays.
Combination therapies exploration (e.g., GLP-1 + amylin analogues). [oai_citation:17‡PubMed](https://pubmed.ncbi.nlm.nih.gov/36883831/?utm_source=chatgpt.com)

Energy Balance & Gastrointestinal Dynamics

Gastric-emptying delay, food-intake measurement, brain satiety signalling (hypothalamus, area postrema).
Cross-talk between pancreatic hormones (insulin, amylin) and central regulators. [oai_citation:18‡Peptide Sciences](https://www.peptidesciences.com/cagrilintide-10mg?utm_source=chatgpt.com)

Synergistic Peptides (for Study Design)

Semaglutide

Why pair: A GLP-1 receptor agonist with well-established weight-loss and glycaemic control effects; pairing with cagrilintide leverages **different but complementary pathways** (amylin + GLP-1). [oai_citation:19‡Pharmacy Times](https://www.pharmacytimes.com/view/co-formulation-of-semaglutide-and-cagrilintide-shows-promise-against-diabetes-and-obesity?utm_source=chatgpt.com)
Angle: Design head-to-head or additive studies to test whether amylin-pathway activation adds benefit to GLP-1 alone.

Retatrutide

Why pair: A triple-agonist peptide (GLP-1/GIP/glucagon) that expands metabolic mechanism space; combining with an amylin analog may enhance energy-balance readouts. [oai_citation:20‡The New England Journal of Medicine](https://www.nejm.org/doi/full/10.1056/NEJMoa2502081?utm_source=chatgpt.com)
Angle: Multi-agonist designs exploring satiety + caloric-burn + insulin responses simultaneously.

MOTS-c

Why pair: A mitochondrial-derived peptide influencing energy-metabolism; useful in designs where weight-loss interventions include mitochondrial/energy-burn endpoints.
Angle: Combine feeding/appetite suppression (cagrilintide) with mitochondrial function metrics (MOTS-c) for comprehensive metabolic studies.

Design Notes

Specify dosing frequency (once-weekly), vehicle, salt/acetylation form; amylin analogues are sensitive to amyloid-/aggregation potential. [oai_citation:21‡Creative Peptides](https://www.creative-peptides.com/resources/what-is-cagrilintide-peptide.html?utm_source=chatgpt.com)
Ensure baseline diet/exercise control in models—appetite suppression may interact with behavioural confounds.

Known Concerns (Context)

Gastrointestinal side-effects: In human trials nausea, constipation, diarrhea were more frequent compared to placebo. [oai_citation:22‡PubMed](https://pubmed.ncbi.nlm.nih.gov/34798060/?utm_source=chatgpt.com)
Long-term human safety: Although promising, long-term data (especially beyond 2-3 years) remain limited; careful translation required. [oai_citation:23‡PubMed](https://pubmed.ncbi.nlm.nih.gov/36883831/?utm_source=chatgpt.com)
General: Research-use only; not approved for therapeutic use in many jurisdictions. Buyer must ensure proper handling and compliance.

Specifications & Handling

Form: Lyophilised powder (lot-coded) — verify salt/acylation form.
Purity: Typically ≥ 99 % (HPLC-verified) in research grade. [oai_citation:24‡NovoPro Labs](https://www.novoprolabs.com/p/cagrilintide-319572.html?utm_source=chatgpt.com)
Storage: ≤ −20 °C; protect from light/moisture; minimise freeze–thaw cycles.

In solution: Prepare fresh aliquots; record vehicle pH, temperature, and tube type.
Packaging: Tamper-evident; labelled “research-use only” where required.

Regulatory & Use Notice

Sold for laboratory research use only. Not for human consumption, medical, or veterinary use. No human-use instructions are provided. Buyer is responsible for safe handling and regulatory compliance.

Cagrilintide Amylin Analogue Peptide Research | Dual Amylin/Calcitonin Receptor Agonist | Obesity & Metabolic Syndrome Studies

Keywords: Cagrilintide peptide, AM833, long-acting amylin analogue, dual amylin receptor agonist, DACRA, calcitonin receptor agonist, weight-loss research, metabolic peptide, Base Peptides.

View full details

Instructions are NOT provided before or after purchase.

Peptide molecules are unfinished and require reconstitution from a skilled and licensed professional to activate the compound into liquid form. Instructions are not provided for reconstitution, dosing, or adminstration. All products are strictly intended for research purposes and laboratory experimentation. Handling should be by skilled licensed and credentialed professionals only. Non experimental use is strictly prohibited.

Keep Shopping